Dow AgroSciences and Exelixis Announce Research Collaboration

Dow AgroSciences signed a major research collaboration agreement with Exelixis Plant Sciences, a Biotechnology Company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The deal aims to develop new tools for gene discovery and validation of novel crop traits. The agreement includes the purchase of Exelixis' intellectual properties and physical assets used for crop trait discovery by Dow AgroSciences' affiliate Agrigenetics Inc.

"At Dow AgroSciences we continue to add cutting-edge tools to our Research and Development portfolio, and are excited about what this agreement will enable us to add to our existing capabilities," said Daniel R. Kittle, Vice President of Research and Development for Dow AgroSciences. He adds, "This asset purchase and collaboration will accelerate our gene discovery and validation efforts as we work to bring revolutionary solutions for our customers.” Exelixis has previously worked with DowAgrosciences in elucidating the mechanism of action of herbicidal compounds based and on the identification of their gene targets and development of specific target screening assays.

Read the press release at http://ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-newsArticle&ID=1047848&highlight